Action Pharma appoints new chief executive
pharmafile | April 19, 2010 | Appointment | Research and Development | Action Pharma, appointment, research and development
Ingelise Saunders has joined Danish biotech Action Pharma as its new chief executive.
She will be involved in seeking partners for its two lead programmes as well as exploring M&A or consolidation opportunities to strengthen the company.
Saunders has more than 30 years of experience in the international pharmaceutical and biotech industry.
Before joining Action Pharma, she was president and chief executive of ACE BioSciences, Denmark, for five years.
Prior to that, she spent three years in the UK as chief executive of Celltech Pharmaceuticals, where she had with global commercial responsibility, and before that she spent 16 years with Novo Nordisk in senior executive management positions, both in Denmark and in the UK.
“Ingelise represents a very strong executive management career in both the international pharmaceutical and biotech industry. Following a satisfactory outcome of the phase I and II clinical development of its two lead programmes, Action Pharma is now focusing on M&A and partnering. Ingelise brings to the company a very strong track record in these areas,” said Sten Verland, chairman of the board of directors.
These programmes are AP214, which is in phase II development to prevent post-surgical kidney injury after major cardiac surgery, and AP1030, which has completed phase Ib studies in type II diabetes associated with obesity.
Former chief executive Søren Nielsen will take up a position as chief operating officer and continues as part of Action Pharma’s executive management group.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
